🇪🇺#европа #отчетности
Roche Q1 Earnings:
-Sales: CHF15.14B (est CHF14.83B)
-Avastin Sales: CHF1.50B (est CHF1.56B)
-Herceptin Sales: CHF1.21B (est CHF1.29B)
-Outlook For 2020 Confirmed
Roche Q1 Earnings:
-Sales: CHF15.14B (est CHF14.83B)
-Avastin Sales: CHF1.50B (est CHF1.56B)
-Herceptin Sales: CHF1.21B (est CHF1.29B)
-Outlook For 2020 Confirmed
🇪🇺#европа #отчетности
Ericsson Q1 Earnings:
-Net Sales: SEK49.8B (est SEK51.9B)
-Operating Margin: 9.3% (vs. 7.2%)
-Q2 Likely To Be A Tad Softer Than Normal
-Adj Operating Profit: SEK4.6B (est SEK4.06B)
-Adj Gross Margin: 40.4% (est 37.9%)
-Sees 2020 Ran Market Growth Of 4%; Lower Growth In Q2
Ericsson Q1 Earnings:
-Net Sales: SEK49.8B (est SEK51.9B)
-Operating Margin: 9.3% (vs. 7.2%)
-Q2 Likely To Be A Tad Softer Than Normal
-Adj Operating Profit: SEK4.6B (est SEK4.06B)
-Adj Gross Margin: 40.4% (est 37.9%)
-Sees 2020 Ran Market Growth Of 4%; Lower Growth In Q2
🇪🇺#европа #отчетности
STMicro Electronics Q1 Earnings:
-Net Revenue: $2.23B
-Gross Margin: 37.9%
-Sees 2Q Net Rev: $2B (vs/$2.23B In Q1)
-Sees Q2 Gross Margin: 34.6% +/- 200bps
-Sees FY Capex: $1B To $1.2B (prev saw $1.5B)
STMicro Electronics Q1 Earnings:
-Net Revenue: $2.23B
-Gross Margin: 37.9%
-Sees 2Q Net Rev: $2B (vs/$2.23B In Q1)
-Sees Q2 Gross Margin: 34.6% +/- 200bps
-Sees FY Capex: $1B To $1.2B (prev saw $1.5B)
🇪🇺#европа #отчетности
Akzo Nobel Q1 Earnings:
-Revenue: EUR2.06B (est EUR1.99B)
-Adj Operating Income: EUR214M (est EUR173.2M)
-Covid-19 Headwinds To Have Significant Impact During Q2
-Suspends 2020 Financial Ambition
Akzo Nobel Q1 Earnings:
-Revenue: EUR2.06B (est EUR1.99B)
-Adj Operating Income: EUR214M (est EUR173.2M)
-Covid-19 Headwinds To Have Significant Impact During Q2
-Suspends 2020 Financial Ambition